A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002

Liver Transplantation

Volumn 8, Issue 1, 2002, Pages 2-9

  Vargas, Hugo E ^a   Dodson, Forrest S ^b   Rakela, Jorge ^a  

^a MAYO CLINIC   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA1 INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; FAMCICLOVIR; FIALURIDINE; FOSCARNET; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LACTIC ACID; LAMIVUDINE; LOBUCAVIR; POLYCLONAL ANTIBODY; VIRUS DNA; VITRONECTIN;

CHRONIC HEPATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LACTIC ACIDOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PATIENT CARE; PRIORITY JOURNAL; RECIPIENT; RECURRENT INFECTION; REVIEW; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 0036149668     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.29765     Document Type: Article

References (89)

1. Immunosuppression, liver injury, and hepatitis in renal, hepatic, and cardiac homograft recipients: With particular reference to the Australia antigen
2. Liver transplantation in a 27-year-old female with familial HBsAg-positive hepatocellular carcinoma
3. Familial HBsAg-positive hepatoma: Treatment with orthotopic liver transplantation and specific immunoglobulin
4. Liver allograft. Its use in chronic active hepatitis with macronodular cirrhosis, hepatitis B surface antigen
5. Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection
6. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
7. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
8. Liver transplantation in hepatitis delta virus disease
9. Immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts
10. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts
11. Simultaneous passive-active immunization for preventing hepatitis B virus reinfection in hepatitis B surface antigen-positive liver transplant recipients
12. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
13. Long-term passive immunoprophylaxis of B virus recurrence after liver transplantation in HBs antigen-positive patients
14. B hepatitis and liver transplantation
15. Liver transplantation in European patients with the hepatitis B surface antigen
16. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization
17. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
18. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection
19. Should liver transplantation be performed for patients with chronic hepatitis B? Yes!
20. Liver transplantation for hepatitis B
21. Hepatitis B immune globulin: The US experience
22. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
23. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review
24. Modulation of the immunological response to hepatitis B virus by antibodies
25. Human monoclonal antibody against hepatitis B surface antigen in preventing recurrent hepatitis B following liver transplantation
26. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients
27. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
28. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
29. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
30. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis
31. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation
32. Vaccine-induced escape mutant of hepatitis B virus
33. Emergence of hepatitis B virus S gene mutant in a liver transplant recipient
34. Hepatitis B virus surface mutations associated with infection after liver transplantation
35. Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation
36. Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence
37. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
38. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
39. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation
40. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
41. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up
42. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
43. Lamivudine as initial treatment for chronic hepatitis B in the United States
44. A one-year trial of lamivudine for chronic hepatitis B
45. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: For whom and when?
46. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
47. Survival in chronic hepatitis B. An analysis of 379 patients
48. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis
49. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
50. Clinical potential of emerging new agents in hepatitis B
51. Antiviral therapy to prevent and treat hepatitis B virus infection in hepatic allografts
52. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
53. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
54. Adefovir dipivoxil suppresses lamivudine resistant hepatitis B virus in liver transplant recipients
55. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
56. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus
57. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation
58. Developing strategies for prevention and treatment of recurrent HBV in liver transplantation
59. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation
60. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation
61. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as flow -dose hepatitis B immune globulin
62. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B
63. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations
64. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient
65. Immunohistochemical (IHCS) positivity for HBsAg and HBcAg of liver biopsy after OLT for hepatitis B (HBV) is not predictive of recurrence in patients treated with HBV immune globulin (H-BIG)
66. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation
67. Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B
68. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model
69. Interferon alfa for recurrent hepatitis B infection after liver transplantation
70. Lack of sustained efficacy of combination ganciclovir and foscarnet for hepatitis B virus recurrence after liver transplantation
71. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation
72. Treatment of hepatitis B reinfection or de novo-infection after liver transplantation with famciclovir-How effective is it?
73. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation
74. Posttransplantation prevention and treatment of recurrent hepatitis B
75. Long term follow-up of lamivudine therapy for hepatitis B before and after liver transplantation: Clinical implication of development of the YMDD mutant
76. "Occult" hepatitis B virus as source of infection in liver transplant recipients
77. Infectivity of hepatic allografts with antibodies to hepatitis B virus
78. Development of hepatitis-B infection after liver transplantation with donor livers from patients with HBcAb and HBsAb
79. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen
80. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature
81. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen
82. Serological evidence of past hepatitis B infection in liver donor and hepatitis B infection in liver allograft
83. Hepatitis B transmission from a liver donor who tested negative for hepatitis B surface antigen and positive for hepatitis B core antibody
84. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population
85. Liver transplantation and de novo hepatitis B infection
86. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors
87. De novo and apparent de novo hepatitis B virus infection after liver transplantation
88. The impact of anti-hepatitis Bc positive grafts on the outcome of liver transplantation for HBV-related cirrhosis
89. Single-center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe